"....I would assume the Zen announcement bodes well for RVX given its another conformation of the bioactivity and safety of the numerous compounds in both companies?"

Zenith and Resverlogix are the leaders in BET bromodomain inhibitor field. So I agree, success of one bolsters the reputation and confidence in the other.

"To me, it shows RVX/ZENs capacity to churn new reliable compounds with limited cash. Imagine you do 10x their budget, I'm sure the potential is incredible. There's more than ABL and ZEN-3694. There's the star factory behind those two. Worth a lot."

Exactly. Both companies have thousands of compounds with varying BET protein and bromodomain specificity. Many additional compounds ready to enter clinical trials after extensive pre-clinical validation. These companies are dedicated to BET bromodomain inhibitors. They likely know more about BET inhibitor biology than any other company or academic lab. This star factory is worth a ton, as you pointed out.

BDAZ